Ignite Creation Date:
2025-12-24 @ 4:41 PM
Ignite Modification Date:
2026-04-16 @ 2:43 PM
Study NCT ID:
NCT06751966
Status:
RECRUITING
Last Update Posted:
2024-12-30
First Post:
2024-12-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
Sponsor:
The First Affiliated Hospital of Nanchang University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
ISL2024314
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None